Treatment of primary erythromelalgia with cyclosporine [6]

New England Journal of Medicine

Volumn 349, Issue 8, 2003, Pages 816-817

  Sano, Shigetoshi ^a   Itami, Satoshi ^a   Yoshikawa, Kunihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ADULT; ARTERIOVENOUS SHUNT; CASE REPORT; CHROMOSOME 2; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; ERYTHROMELALGIA; FEMALE; GENETIC DISORDER; HUMAN; HYPERTENSION; LETTER; NEPHROTOXICITY; PRIORITY JOURNAL; GENETICS;

ADULT; CYCLOSPORINE; ERYTHROMELALGIA; FEMALE; HUMANS;

EID: 0041965983     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200308213490821     Document Type: Letter

References (5)

1. Finley WH, Lindsey JR Jr, Fine JD, Dixon GA, Burbank MK. Autosomal dominant erythromelalgia. Am J Med Genet 1992;42:310-5.
2. Drenth JP, Finley WH, Breedveld GJ, et al. The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32. Am J Hum Genet 2001;68:1277-82.
3. Mork C, Asker CL, Salerud EG, Kvernebo K. Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia. J Invest Dermatol 2000;114:643-6.
4. Marumo T, Nakaki T, Hishikawa K, Suzuki H, Kato R, Saruta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 1995;25:764-8.
5. Abassi ZA, Pieruzzi F, Nakhoul F, Keiser HR. Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rat. Hypertension 1996;27:1140-8.